2014
DOI: 10.1002/2055-5822.12002
|View full text |Cite
|
Sign up to set email alerts
|

Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival

Abstract: Background Male ageing is characterized by diminished circulating androgens with several adverse psychosomatic consequences and can be aggravated by concomitant chronic diseases. According to the European Male Aging Study (EMAS) Group, late-onset hypogonadism (LOH) refers to testosterone deficiency accompanied by sexual complaints.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2016
2016
2016
2016

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…A number of treatments have been suggested for cachexia; however, therapies for the underlying illness remain at the forefront, and no direct treatment of cachexia is available as yet. The multifactorial nature of cachexia and muscle wasting is now much better understood, and particularly the role of inflammatory mediators, and the imbalance of anabolism and catabolism are considered important therapeutic targets . Several approaches to develop cachexia and muscle wasting treatments have failed to be successful in phase III clinical trials, but new approaches are in development.…”
Section: Estimates For the Prevalence Of Cachexia In Several Chronic mentioning
confidence: 99%
“…A number of treatments have been suggested for cachexia; however, therapies for the underlying illness remain at the forefront, and no direct treatment of cachexia is available as yet. The multifactorial nature of cachexia and muscle wasting is now much better understood, and particularly the role of inflammatory mediators, and the imbalance of anabolism and catabolism are considered important therapeutic targets . Several approaches to develop cachexia and muscle wasting treatments have failed to be successful in phase III clinical trials, but new approaches are in development.…”
Section: Estimates For the Prevalence Of Cachexia In Several Chronic mentioning
confidence: 99%